Lexicon Pharmaceuticals Reports 2nd Quarter Financial Results, Provides Clinical Pipeline Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
JPMorgan Downgrades Lexicon Pharmaceuticals (LXRX) to Neutral
August 10, 2015 6:45 AM EDTJPMorgan downgraded Lexicon Pharmaceuticals (NASDAQ: LXRX) from Overweight to Neutral with a price target of $14.00 (from $9.00).
For an analyst ratings summary and ratings history on Lexicon Pharmaceuticals click here. For more ratings news on Lexicon Pharmaceuticals click here.
Shares of Lexicon Pharmaceuticals closed at $11.38 yesterday.
... MoreLexicon Pharma (LXRX) Tops Q2 EPS by 5c
August 7, 2015 7:30 AM EDTLexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.27), $0.05 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $376 million versus the consensus estimate of $360 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
... More